MMED:CC News and Press, MIND MEDICINE INC. From 06/20/23

Psilocybin is one of several psychedelics that have exhibited therapeutic potential against various common mental disorders. Research has revealed that psilocybin (magic mushrooms) can deliver long-term benefits against mental disorders such as depression, anxiety, and substance-abuse disorders...

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, will provide an overview of clinical progress and corporate updates ...

Meeting Will Resume on Wednesday, June 21, 2023 Believes FCM Has Made Deliberate Efforts to Prevent Quorum from Being Achieved MindMed Encourages Shareholders to Vote FOR All Six of the Company’s Director Candidates on the WHITE Universal Proxy Card Mind Medicine ...

Lawmakers in Nevada have approved a bill that would create a psychedelic working group to study hallucinogenics and aid in the development of a therapeutic psychedelic market in the state. Recent efforts by scientists across the country have shown that psychedelics, long considered by federal l...

Proxy Cards Must be Received by 10:00 AM EDT on Tuesday, June 13 th for Votes to Count Encourages Shareholders to Vote on the WHITE Universal Proxy Card FOR ALL SIX of the Company’s Director Nominees Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: M...

Both Leading Proxy Advisory Firms – ISS and Glass Lewis – Now Recommend Support For All MindMed’s Nominees and Concluded FCM Has Not Made a Compelling Case for Change Glass Lewis Notes Company’s Director Nominees Possess the “Appropriate Experience and Q...

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that its management team will a host an Analyst Day ...

Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120 Canada NewsWire VANCOUVER, BC , June 5, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMI...

Like medical cannabis a few years ago, psychedelics have now captured the public consciousness due to their medical potential. Research into psychedelics has revealed that they can treat many mental health disorders with minimal side effects. With millions of Americans currently struggling wi...

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team...